Utility of 18F-FDG PET/CT in risk assessment of Medication-related osteonecrosis of jaw.

IF 0.9 4区 医学 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Hellenic journal of nuclear medicine Pub Date : 2025-01-01 Epub Date: 2025-04-07 DOI:10.1967/s002449912782
Kazuhiro Kitajima, Kazuma Noguchi, Kuniyasu Moridera, Kyohei Yoshikawa, Kazuki Takaoka, Hiromitsu Kishimoto, Yukihisa Tamaki, Koichiro Yamakado
{"title":"Utility of <sup>18</sup>F-FDG PET/CT in risk assessment of Medication-related osteonecrosis of jaw.","authors":"Kazuhiro Kitajima, Kazuma Noguchi, Kuniyasu Moridera, Kyohei Yoshikawa, Kazuki Takaoka, Hiromitsu Kishimoto, Yukihisa Tamaki, Koichiro Yamakado","doi":"10.1967/s002449912782","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The clinical utility of quantitative fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (<sup>18</sup>F-FDG PET/CT) for classification of medication-related osteonecrosis of the jaw (MRONJ) was determined.</p><p><strong>Subjects and methods: </strong>Seventy-one lesions in 59 patients clinically diagnosed as MRONJ, based on American Association of Oral and Maxillofacial Surgeons (AAOMS) diagnostic criteria by Japanese Society of Oral Surgery specialists and who received <sup>18</sup>F-FDG PET/CT examinations, were enrolled. For analysis, standard uptake values (SUV), including maximum (SUVmax), peak (SUVpeak), and mean (SUVmean) were evaluated, and also metabolic lesion volume (MLV) for total volume above the threshold, and total lesion glycolysis (TLG), calculated as MLVxSUVmean. To compare quantitative values between clinical stages, one-way repeated measures analysis of variance and subsequent post-hoc analysis were used.</p><p><strong>Results: </strong>The mean SUVmax values for AAOMS stage 1 (n=13), 2 (n=43), and 3 (n=15) patients were 3.68±0.83, 6.15±1.32, and 9.92±1.63, respectively, while MLV values were 6.51±5.53, 8.76±9.74, and 13.92±13.89, respectively, and TLG values were 16.84±17.23, 31.36±35.25, and 66.27±58.51, respectively. Maximum SUV and TLG showed significant differences between clinical stages (P<0.0001 and P=0.0029, respectively). With stage increase, MLV showed a mild increasing tendency, though the difference between stages was not significant (P=0.13), while SUVmax value differences between individual stages were significant in subsequent post-hoc analysis (P<0.0001). Furthermore, post-hoc analysis indicated that the stage 3 TLG value was significantly greater than that of stage 1 and 2 (P<0.01 and P<0.05, respectively).</p><p><strong>Conclusion: </strong>For MRONJ patients, SUVmax and TLG derived from quantitative <sup>18</sup>F-FDG PET/CT results are reliable objective indicators useful for disease activity evaluation and staging.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":" ","pages":"14-19"},"PeriodicalIF":0.9000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hellenic journal of nuclear medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1967/s002449912782","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/7 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: The clinical utility of quantitative fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) for classification of medication-related osteonecrosis of the jaw (MRONJ) was determined.

Subjects and methods: Seventy-one lesions in 59 patients clinically diagnosed as MRONJ, based on American Association of Oral and Maxillofacial Surgeons (AAOMS) diagnostic criteria by Japanese Society of Oral Surgery specialists and who received 18F-FDG PET/CT examinations, were enrolled. For analysis, standard uptake values (SUV), including maximum (SUVmax), peak (SUVpeak), and mean (SUVmean) were evaluated, and also metabolic lesion volume (MLV) for total volume above the threshold, and total lesion glycolysis (TLG), calculated as MLVxSUVmean. To compare quantitative values between clinical stages, one-way repeated measures analysis of variance and subsequent post-hoc analysis were used.

Results: The mean SUVmax values for AAOMS stage 1 (n=13), 2 (n=43), and 3 (n=15) patients were 3.68±0.83, 6.15±1.32, and 9.92±1.63, respectively, while MLV values were 6.51±5.53, 8.76±9.74, and 13.92±13.89, respectively, and TLG values were 16.84±17.23, 31.36±35.25, and 66.27±58.51, respectively. Maximum SUV and TLG showed significant differences between clinical stages (P<0.0001 and P=0.0029, respectively). With stage increase, MLV showed a mild increasing tendency, though the difference between stages was not significant (P=0.13), while SUVmax value differences between individual stages were significant in subsequent post-hoc analysis (P<0.0001). Furthermore, post-hoc analysis indicated that the stage 3 TLG value was significantly greater than that of stage 1 and 2 (P<0.01 and P<0.05, respectively).

Conclusion: For MRONJ patients, SUVmax and TLG derived from quantitative 18F-FDG PET/CT results are reliable objective indicators useful for disease activity evaluation and staging.

18F-FDG PET/CT在药物相关性颌骨骨坏死风险评估中的应用
目的:探讨定量氟-18-氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描(18F-FDG PET/CT)在药物相关性颌骨骨坏死(MRONJ)分类中的临床应用价值。研究对象和方法:根据美国口腔颌面外科医师协会(AAOMS)的诊断标准,日本口腔外科学会专家对59例临床诊断为MRONJ的患者进行了18F-FDG PET/CT检查,纳入71例病变。为了进行分析,评估了标准摄取值(SUV),包括最大值(SUVmax)、峰值(SUVpeak)和平均值(SUVmean),以及高于阈值的代谢病变体积(MLV)和总病变糖酵解(TLG),计算为MLVxSUVmean。为了比较临床分期之间的定量值,采用单向重复测量方差分析和随后的事后分析。结果:AAOMS 1期(n=13)、2期(n=43)、3期(n=15)患者的平均SUVmax值分别为3.68±0.83、6.15±1.32、9.92±1.63,MLV值分别为6.51±5.53、8.76±9.74、13.92±13.89,TLG值分别为16.84±17.23、31.36±35.25、66.27±58.51。结论:对于MRONJ患者,18F-FDG PET/CT定量结果得出的SUVmax和TLG是评估疾病活动性和分期的可靠客观指标。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.40
自引率
6.70%
发文量
34
审稿时长
>12 weeks
期刊介绍: The Hellenic Journal of Nuclear Medicine published by the Hellenic Society of Nuclear Medicine in Thessaloniki, aims to contribute to research, to education and cover the scientific and professional interests of physicians, in the field of nuclear medicine and in medicine in general. The journal may publish papers of nuclear medicine and also papers that refer to related subjects as dosimetry, computer science, targeting of gene expression, radioimmunoassay, radiation protection, biology, cell trafficking, related historical brief reviews and other related subjects. Original papers are preferred. The journal may after special agreement publish supplements covering important subjects, dully reviewed and subscripted separately.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信